OBJECTIVES: Patient-driven titration has been proven as efficacious and safe as physician-driven titration of Biphasic Insulin Aspart 30 (BIAsp 30) in people with type 2 diabetes (T2DM) in China in the 20-week trial (ClinicalTrials.gov identifier: NCT01618214).This study was to further compare titration-related healthcare utilizations and costs associated with BIAsp 30 self-driven versus physician-driven titration in China based on this trial. METHODS: RESULTS: During the 20-week trial period, healthcare utilization associated with self-driven titration was lower than that with physician-driven titration (mean number of SMPG was 147.15 versus 151.31(P=0.5178), outpatient visits was 5.69 versus 8.86 (P<0.001), calls was 5.94 versus 5.98 (P=0.1956), and there were no titration-related hospitalizations in both groups). Average total titration-related costs were CNY 424.93 lower in self-driven group than in physician-driven group (total cost was CNY 1654.14 versus CNY 2079.07; direct medical cost was CNY 1151.31 versus CNY 1329.06; transportation cost was CNY 360.61 versus CNY 537.88; and indirect cost was CNY 142.22 versus CNY 212.13). CONCLUSIONS: Self-driven titration of BIAsp 30 was associated with less healthcare utilization and lower costs compared to physician-driven titration in people with T2DM in China. The new evidence suggests that a more patient-focused approach towards diabetes management may be cost-saving and improve overall efficiency.